First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort
Cancer Immunology, Immunotherapy · 2026
DOI: 10.1007/s00262-026-04313-2 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Tanya Ramadoss und 11 weiteren Autor:innen. Beteiligte Einrichtung: Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine, Davie, FL, USA. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Ipilimumab, Nivolumab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Barry S. Greene Fund.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine, Davie, FL, USA.
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
- Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA.
- Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL, USA.
- Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA. andrew.brohl@moffitt.org.
- Sarcoma Department, Moffitt Cancer Center, Tampa, FL, USA. andrew.brohl@moffitt.org.
Förderung
- Barry S. Greene Fund
Zitieren
APA
Ramadoss, T., Palacios, C., Nichols, M., Eroglu, Z., Markowitz, J., Karapetyan, L., Tarhini, A. A., Wuthrick, E. J., Sondak, V. K., Tsai, K. Y., Khushalani, N. I., & Brohl, A. S. (2026). First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04313-2
Vancouver
Ramadoss T, Palacios C, Nichols M, Eroglu Z, Markowitz J, Karapetyan L, et al. First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04313-2
BibTeX
@article{Ramadoss2026,
author = {Ramadoss, Tanya and Palacios, Christian and Nichols, Matthew and Eroglu, Zeynep and Markowitz, Joseph and Karapetyan, Lilit and Tarhini, Ahmad A and Wuthrick, Evan J and Sondak, Vernon K and Tsai, Kenneth Y and Khushalani, Nikhil I and Brohl, Andrew S},
title = {First-line ipilimumab plus nivolumab in advanced merkel cell carcinoma: a meta-analysis of prospective trials and real-world validation cohort},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-026-04313-2}
}
EUVIMED